Infant Formula Ingredients Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Rising Parental Awareness of Infant Nutrition

Parents' growing understanding of nutrition and increased access to digital health platforms are driving significant changes in consumer behavior, particularly in their demand for detailed transparency in ingredient formulations and nutrient absorption data. Access to evidence-based parenting information has changed formula purchasing decisions in the infant formula ingredients market. Parents are examining labels more closely and seeking ingredients supported by nutritional and clinical evidence. This behavior increases demand for validated components across both premium and mid-tier products. Formula manufacturers must therefore secure reliable access to clinical-grade bioactive ingredients to maintain product specifications. That requirement can place pressure on manufacturers that lack long-term supply arrangements. It also supports the position of suppliers with documented safety and application capabilities.

Demand for Functional and Specialty Ingredients

The infant formula ingredients market is shifting toward products designed to more closely reflect selected functions of breast milk. More than 12 HMO structures are commercially available in 2026, compared with 2-3 a decade earlier, allowing manufacturers to develop multi-HMO blends. DSM-Firmenich and Novonesis are pairing HMOs with selected probiotic strains to support synbiotic positioning. A 2025 randomized trial found that a partially hydrolyzed whey formula containing 6 manufactured HMOs and 2 probiotic strains was safe, well tolerated, and associated with improved gut health measures. These findings give formula brands a documented basis for differentiation above conventional probiotic-only products. The wider availability of such ingredient systems is raising the functional standard expected in the premium segment.

Government-Funded Fortification Mandates

National nutrition programs support continuing demand for vitamins, minerals, and protein matrices in the infant formula ingredients market. India’s Poshan Abhiyaan continues to support nutrition and micronutrient infrastructure across the country^[2]. Codex Standard CXS 72-1981 sets requirements for infant formula and formulas for special medical purposes intended for infants. Countries aligning domestic rules with Codex may require manufacturers to upgrade ingredients and product specifications. Smaller producers that previously used inputs below international standards can face reformulation requirements. This favors suppliers that already hold recognized regulatory and safety documentation.

Commercialization of Precision-Fermented HMOs

Precision fermentation is improving the availability of HMO ingredients in the infant formula ingredients market. DSM-Firmenich received approval for GLYCARE 2'-FL and LNnT in China and approval for GLYCARE 2'-FL in India during 2025. China established a regulatory basis for the use of 2'-FL and LNnT as food nutritional fortifiers. FDA GRAS reviews and the European Union Novel Food process remain important gates for new HMO structures. Suppliers that can complete these processes can access high-value formula applications. The resulting regulatory requirements favor companies with fermentation expertise and established evidence packages.

Intensifying Advocacy for Breastfeeding as the Optimal Choice

The World Health Assembly adopted a May 2025 resolution that allows member states to request WHO support for regulating digital marketing of breast-milk substitutes. The measure covers social media, influencer activity, and targeted online advertising. Restrictions in these channels can make it more difficult for formula brands to reach first-time parents, particularly in emerging markets. Higher customer acquisition costs can affect the growth of premium and specialty formula products. Ingredient suppliers are indirectly exposed when their customers depend heavily on digital brand building. The infant formula ingredients market must therefore account for marketing restrictions alongside product and safety regulations.

Food Allergy and Intolerance Prevalence

Cow milk protein allergy affects 2-3% of infants globally and increases demand for specialized formulas. This demand requires extensively hydrolyzed proteins and amino acid-based inputs that need advanced fractionation and quality controls. The infant formula ingredients market benefits from the value created by specialty formulas, but suppliers must meet more demanding technical requirements. Companies without validated hydrolysis and purification capabilities may be excluded from these clinical applications. This can concentrate specialty ingredient supply among vertically integrated processors. The main constraint is the added cost and sourcing complexity rather than a direct decline in clinical demand.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Infant Formula Ingredients Market Segment Analysis

Carbohydrates represented the largest market segment, accounting for a 39.68% share in 2025, primarily due to sustained lactose demand from traditional formula manufacturers. The prebiotics and probiotics segment is expected to register a CAGR of 8.16% through 2031. Within the protein segment, precision fermentation facilitates the production of human casein micelles, offering superior digestibility and nutrient absorption relative to bovine proteins. Growth in the vitamins and minerals segment is reinforced by government fortification mandates, especially in emerging markets where regulations targeting micronutrient deficiencies necessitate enhanced supplementation.

Food Standards Australia New Zealand approved MFGM-WPC as a nutritive substance in infant formula in 2025^[3]. Proteins, vitamins, minerals, and HMOs complete the major ingredient groups. Lactoferrin and bioactive whey fractions support clinically differentiated products, while Glanbia Nutrition identifies early-life nutrition as an application area. HMOs are smaller by volume but are becoming more widely available as commercial options expand. Nucleotides, taurine, and structured lipids support nutritional completeness and product differentiation.

Cow milk led the source segment with a 67.46% share in 2025 because it has broad supply infrastructure, cost efficiency, and regulatory acceptance. Goat milk is the fastest-growing source, at an 8.11% CAGR through 2031. Its A2-dominant beta-casein profile and smaller fat globules support its use for infants with mild digestive sensitivity. Soy and protein hydrolysates are used in medically indicated formulations. ESPGHAN’s 2025 public consultation on biotics in infant and follow-on formulas illustrates the continuing clinical focus on product composition.

Cow milk remains central to volume supply, but its value profile is changing as manufacturers add bioactive components. Commodity fractions face margin pressure when customers seek specialized nutrition claims. Goat whey protein concentrates and demineralized whey powder are important inputs for goat milk formulas. Species segregation and composition validation can support premium pricing for suppliers that maintain consistent specifications. The infant formula ingredients industry is therefore using source selection as both a nutritional and commercial choice.

Powder accounted for 72.61% of the infant formula ingredients market size in 2025. Its lead is supported by shelf-life advantages, reduced cold-chain dependence, and established distribution systems. Liquid and semi-liquid products are forecast to grow at a 7.78% CAGR through 2031. Hospitals and neonatal intensive care units use sterile ready-to-feed products to reduce reconstitution error for preterm and immunocompromised infants. The FDA’s review of formula nutrient requirements is also increasing attention on product controls in the United States and the infant formula ingredients market.

The European Union maintains detailed limits for contaminants in infant formula products, which can favor producers with established analytical testing programs. Powder is expected to remain the principal format because it serves cost-sensitive and geographically dispersed markets. Ready-to-feed products can gain value in clinical channels where precision and safety carry greater weight. FrieslandCampina Ingredients reported plans to expand MFGM and whey protein isolate capacity for early-life nutrition applications. These investments can support both powder and liquid product development.

Conventional certification held 73.62% of the segment in 2025 because conventional dairy matrices remain accessible across a broad range of markets. Organic products are projected to record the highest growth across the reported segmentation types, at an 8.55% CAGR through 2031. This performance reflects continuing clean-label interest among parents seeking certified ingredients in the infant formula ingredients market. EU rules set composition and labeling requirements for infant and follow-on formulas. Commission Delegated Regulation EU 2025/2017 strengthened criteria for certain protein hydrolysate formulations, which can favor companies with established evidence and compliance capabilities.

Organic sourcing adds complexity through certified dairy procurement and traceability requirements, which can favor established cooperatives with deeper farm-level networks. Organic goat milk combines clean-label and digestibility claims within one product position. This combination is relevant to premium products in China, Australia, and the United Kingdom. Conventional inputs will remain important because they offer lower cost and wider availability. The infant formula ingredients market therefore retains room for both certified organic inputs and conventional supply systems.

Standard Infant Formula Stage 1 held 47.12% of the infant formula ingredients market size in 2025. It is used as the sole nutritional source for non-breastfed infants from birth to 6 months under Codex and national rules. Specialty formulas are the fastest-growing application category, with an 8.37% CAGR through 2031. Demand is linked to clinical needs such as cow milk protein allergy. These formulations require higher-value hydrolysates and amino acid ingredients, and Carbery identifies infant nutrition as a market focus.

Follow-On Formula Stage 2 and Growing-Up Milk Stage 3 cover the 6-36-month period. Manufacturers are aligning their specifications with premium Stage 1 positions to strengthen product continuity. ESPGHAN’s work on probiotics, prebiotics, synbiotics, postbiotics, and HMO analogues continues to influence clinically oriented formula development. Specialty inclusion in later-stage products can help brands sustain premium value beyond infancy. This keeps specialty formulas important to value creation in the infant formula ingredients industry.

Geography Analysis

APAC and America Infant Formula Ingredients Market

Asia-Pacific accounted for 55.33% of total market value in 2025 and is forecast to grow at an 8.34% CAGR through 2031. China remains the largest country-level opportunity in the region, supported by its GB standards framework. India is gaining importance after approvals for DSM-Firmenich GLYCARE 2'-FL and Novonesis MyOli 5HMOMIX broadened access to commercially produced HMOs. DSM-Firmenich reported approval for GLYCARE 2'-FL in India during 2025. Thailand approved FrieslandCampina Ingredients’ Vivinal MFGM for infant formula use in February 2025.

North America and Europe are the second- and third-largest geographic blocks. North American demand is shaped by premium organic, specialty, and hypoallergenic products. The FDA’s Operation. Europe has a closely updated regulatory framework for infant formula and specialized formulations. Regulation EU 2025/2017 updated technical requirements for certain protein hydrolysate formulas.

South America, the Middle East, and Africa are smaller segments in the infant formula ingredients market but offer longer-term potential. Brazil benefits from urbanization and demand for premium formula products, while the Middle East and Africa are seeing rising formula use alongside urban growth and expanding hospital births. These markets remain import dependent, which increases exposure to supply disruption and currency movements. The UAE and Saudi Arabia are developing as premium formula distribution hubs with retail and cold-chain infrastructure that can support bioactive-enriched products.

Europe Infant Formula Ingredients Market

The United States and Canada show increased consumer demand for hypoallergenic, organic, and specialty formulas due to growing parental awareness of food sensitivities and functional nutrition. Ingredient manufacturers are developing plant-based proteins, non-GMO sources, and bioactive components to address these requirements. Europe maintains regulatory oversight through EFSA's assessment procedures for novel ingredients, with human-identical milk oligosaccharides receiving multiple approvals in 2024. The region's emphasis on sustainability and clean label formulations increases demand for organic and precision-fermented ingredients.

LATAM and MEA Infant Formula Ingredients Market

Latin America shows growth potential, driven by improving birth rates in Brazil and Mexico, and increasing urbanization that enhances access to modern retail and healthcare. Government nutrition programs and public-private partnerships improve early-life nutrition awareness, benefiting formula manufacturers. The market is moving toward fortified formulas with functional proteins, essential fatty acids, and prebiotics to address micronutrient deficiencies and gut health. The Middle East and Africa market continues to develop, supported by rising incomes, urbanization, and women's workforce participation, resulting in increased demand for infant nutrition products.